Clinical trials: Empagliflozin
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Acromegaly, Cardiomyopathies
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly.
- Trial name
- NCT04520646
- Testing
- Empagliflozin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Huashan Hospital
Ascites Hepatic
Empagliflozin as a Novel Therapy in Refractory Ascites
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients…
- Trial name
- NCT05430243
- Testing
- Empagliflozin 10 MG, Diuretics
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Alexandria University
Reperfusion Injury, Myocardial
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
This study is a single-center, prospective controlled trial addressing effectiveness of empagliflozin on cardiac-renal injury in patients with STEMI.
- Trial name
- NCT03591991
- Testing
- Empagliflozin
- Volunteers
- 128 people
- Sponsor
- Chinese PLA General Hospital
Empagliflozin in Cardiorenal Syndrome Type 1
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
- Trial name
- TREAT-CRS (NCT06030843)
- Testing
- Empagliflozin 10 MG
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Autosomal Dominant Polycystic Kidney
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
- Trial name
- EMPA-PKD (NCT06391450)
- Testing
- Empagliflozin 10 MG
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Hannover Medical School
Diabetes Type 2
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2…
- Trial name
- EMPOWER (NCT07771010)
- Testing
- Empagliflozin (Jardiance®), Metformin, Synjardy® 12.5mg/1000mg film-coated tablets
- Where
- Slovenia
- Volunteers
- 54 people
- Sponsor
- University Medical Centre Ljubljana
Type 2 Diabetes Mellitus
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
In traditional step-up approach, the patients with poorly-controlled type 2 diabetes are instructed to take up to 4 insulin injections daily or multiple daily injections (MDI) as the most advanced therapy.
- Trial name
- NCT02846233
- Testing
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Heart Failure, Preserved Ejection Fraction
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
- Trial name
- NCT07047508
- Volunteers
- 3,000 people
- Sponsor
- Boehringer Ingelheim
End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah
Healthy
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs
- Trial name
- NCT02172235
- Testing
- Pioglitazone, Pioglitazone - low dose, BI 10773 - low dose
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI)
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
The goal of this clinical trial is to investigate if a single dose of oral SGLT2i, (50 mg Jardiance) will change oxygen tension in the kidney transplant.
- Conditions
- Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI), Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients
- Trial name
- SGL-TX-MR (NCT06933355)
- Testing
- JARDIANCE 25mg
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Odense University Hospital
Diabetes Mellitus, Type 2
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy in patients with type 2 diabetes…
- Trial name
- LUCID (NCT05103306)
- Testing
- Empagliflozin 25 MG, INS
- Volunteers
- 300 people
- Sponsor
- Chungbuk National University Hospital
Metabolic Syndrome
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS).
- Trial name
- NCT06410352
- Testing
- Semaglutide, Empagliflozin, Minigastric bypass, Analimentary detoxication
- Where
- Kazakhstan
- Volunteers
- 220 people
- Sponsor
- University Medical Center, Kazakhstan
Diabetes Mellitus, Type 2
Performance Under SGLT-2-Inhibitors in Humans
The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the physical performance of patients with Type-II-Diabetes mellitus compared to patients under other therapy regimes.
- Trial name
- PUSH (NCT03422263)
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- Berner Klinik Montana
Type 2 Diabetes Mellitus
Empagliflozin and Sympathetic Nerve Traffic
In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervous activity will be examined.
- Trial name
- NCT03254849
- Testing
- Empagliflozin, Hydrochlorothiazide 25 mg
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Non Alcoholic Steatohepatitis
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate the possible beneficial effect of empagliflozin versus pioglitazone on non-diabetic patients with non-alcoholic steatohepatitis (NASH). This study will be a randomized, comparative parallel study.
- Trial name
- NCT05605158
- Testing
- Pioglitazone 30mg, Empagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Diabetes Mellitus, Type 2
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
The aim of this study is to investigate the cause for the discrepancy in predicted and observed weight loss with Empagliflozin (Jardiance™) by measuring appetite regulation.
- Trial name
- SEESAW (NCT02798744)
- Testing
- Empagliflozin, Diet
- Where
- United Kingdom
- Volunteers
- 68 people
- Sponsor
- University of Leicester
Type 2 Diabetes
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-intensive-careunit setting.
- Trial name
- NCT06187285
- Testing
- Empagliflozin 25 MG, Sitagliptin 100mg
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Medanta, The Medicity, India